Drug resistance in rheumatology: An area in search of investigators Frank A. Wollheim Invited Commentary Pages: 333 - 335
The challenge of following process, damage, and function in patients with rheumatoid arthritis in clinical care Josef S. SmolenDaniel Aletaha Invited Commentary Pages: 336 - 340
Prasterone treatment in systemic lupus erythematosus Rosalind Ramsey-Goldman Clinical Trials Report Pages: 347 - 347
Prasterone treatment in systemic lupus erythematosus Rosalind Ramsey-Goldman Clinical Trials Report Pages: 348 - 348
Prasterone treatment in systemic lupus erythematosus Rosalind Ramsey-Goldman Clinical Trials Report Pages: 348 - 349
B cell depletion therapy in systemic lupus erythematosus Jennifer AnolikIñaki SanzR. John Looney OriginalPaper Pages: 350 - 356
New insights into pregnancy-related complications in systemic lupus erythematosus Doruk ErkanLisa Sammaritano OriginalPaper Pages: 357 - 363
Ethnic disparities in patients with systemic lupus erythematosus América G. UribeGraciela S. Alarcón OriginalPaper Pages: 364 - 369
Evidence-based management of thrombosis in the antiphospholipid antibody syndrome Michelle Petri OriginalPaper Pages: 370 - 373
Autoantibody-associated congenital heart block: The clinical perspective Jill P. BuyonDeborah M. Friedman OriginalPaper Pages: 374 - 378
Mycophenolate mofetil in antiphospholipid syndrome Joan T. Merrill Clinical Trials Report Pages: 381 - 381
Oxidative stress in systemic lupus erythematosus and antiphospholipid syndrome: A gateway to atherosclerosis José Delgado AlvesBruno Grima OriginalPaper Pages: 383 - 390
Catastrophic antiphospholipid syndrome Ronald A. AshersonRicard Cervera OriginalPaper Pages: 395 - 400
The antiphospholipid syndrome and atherosclerosis: Clue to pathogenesis Joan T. Merrill OriginalPaper Pages: 401 - 406